INCYIncyte Genomics Inc

CSNasdaq (XNAS)·USD

Identity

Security key: 17072
Ticker: INCY
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 1993-11-03
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: INCY

Detail

Enriched 2026-08-14 20:47

Market cap: $24,479,806,784.42
Shares outstanding (class): 202,697,746
Shares outstanding (weighted): 202,697,746
SIC: 8731 SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Employees: 2,844
Location: WILMINGTON, DE
Homepage: https://www.incyte.com
Description: Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Market cap and share counts drift.

Funds holding this security

406 funds · 413 positions · $4.58B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
Dodge & Cox Stock Fund Dodge & Cox Funds	—	$779.45M	0.68%	8,281,428 NS	FIGI
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$506.00M	0.03%	5,376,072 NS	FIGI
VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS	VOO	$399.89M	0.03%	4,248,699 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$367.11M	0.22%	3,900,485 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$205.39M	0.53%	2,182,253 NS	FIGI
iShares Core S&P 500 ETF iShares Trust	IVV	$202.30M	0.03%	2,149,426 NS	FIGI
N/A —	—	$182.09M	0.03%	1,934,622 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$138.16M	1.70%	1,467,923 NS	FIGI
VictoryShares Free Cash Flow ETF Victory Portfolios II	VFLO	$136.69M	2.22%	1,452,286 NS	FIGI
State Street(R) Health Care Select Sector SPDR(… SELECT SECTOR SPDR TRUST	XLV	$114.50M	0.30%	1,216,510 NS	FIGI
Dodge & Cox Balanced Fund Dodge & Cox Funds	—	$106.04M	0.72%	1,126,600 NS	FIGI
VANGUARD INSTITUTIONAL INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS	—	$88.66M	0.03%	941,996 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$84.24M	1.13%	895,013 NS	FIGI
First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund	FBT	$71.03M	3.13%	754,631 NS	FIGI
VANGUARD GROWTH AND INCOME FUND VANGUARD QUANTITATIVE FUNDS	—	$57.93M	0.35%	615,488 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERINCY
FIGI_COMPOSITEBBG000BNPSQ9
FIGI_SHARE_CLASSBBG001S8Q6N2
CIK0000879169
ISINUS45337C1027
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Incyte is a biopharmaceutical company focused on oncology, fitting the biotechnology industry within healthcare.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.